192 related articles for article (PubMed ID: 24204569)
1. Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey.
Silvestris N; Pantano F; Ibrahim T; Gamucci T; De Vita F; Di Palma T; Pedrazzoli P; Barni S; Bernardo A; Febbraro A; Satolli MA; Bertocchi P; Catalano V; Giommoni E; Comandone A; Maiello E; Riccardi F; Ferrara R; Trogu A; Berardi R; Leo S; Bertolini A; Angelini F; Cinieri S; Russo A; Pisconti S; Brunetti AE; Azzariti A; Santini D
PLoS One; 2013; 8(10):e74402. PubMed ID: 24204569
[TBL] [Abstract][Full Text] [Related]
2. Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey.
Santini D; Procopio G; Porta C; Ibrahim T; Barni S; Mazzara C; Fontana A; Berruti A; Berardi R; Vincenzi B; Ortega C; Ottaviani D; Carteni G; Lanzetta G; Virzì V; Santoni M; Silvestris N; Satolli MA; Collovà E; Russo A; Badalamenti G; Fedeli SL; Tanca FM; Adamo V; Maiello E; Sabbatini R; Felici A; Cinieri S; Tonini G; Bracarda S
PLoS One; 2013; 8(12):e83026. PubMed ID: 24386138
[TBL] [Abstract][Full Text] [Related]
3. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
[TBL] [Abstract][Full Text] [Related]
4. Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates.
Langer C; Hirsh V
Lung Cancer; 2010 Jan; 67(1):4-11. PubMed ID: 19939491
[TBL] [Abstract][Full Text] [Related]
5. Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting.
Trinkaus M; Simmons C; Myers J; Dranatisaris G; Clemons M
Support Care Cancer; 2010 Feb; 18(2):197-203. PubMed ID: 19424729
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.
Ulas A; Bilici A; Durnali A; Tokluoglu S; Akinci S; Silay K; Oksuzoglu B; Alkis N
Tumour Biol; 2016 Jan; 37(1):1131-40. PubMed ID: 26276360
[TBL] [Abstract][Full Text] [Related]
8. Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study.
Santini D; Tampellini M; Vincenzi B; Ibrahim T; Ortega C; Virzi V; Silvestris N; Berardi R; Masini C; Calipari N; Ottaviani D; Catalano V; Badalamenti G; Giannicola R; Fabbri F; Venditti O; Fratto ME; Mazzara C; Latiano TP; Bertolini F; Petrelli F; Ottone A; Caroti C; Salvatore L; Falcone A; Giordani P; Addeo R; Aglietta M; Cascinu S; Barni S; Maiello E; Tonini G
Ann Oncol; 2012 Aug; 23(8):2072-2077. PubMed ID: 22219016
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications.
Hirsh V; Tchekmedyian NS; Rosen LS; Zheng M; Hei YJ
Clin Lung Cancer; 2004 Nov; 6(3):170-4. PubMed ID: 15555218
[TBL] [Abstract][Full Text] [Related]
10. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases.
Saad F; Chen YM; Gleason DM; Chin J
Clin Genitourin Cancer; 2007 Sep; 5(6):390-6. PubMed ID: 17956712
[TBL] [Abstract][Full Text] [Related]
11. Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations.
Nagata M; Kudoh S; Mitsuoka S; Suzumura T; Umekawa K; Tanaka H; Matsuura K; Kimura T; Yoshimura N; Hirata K
Osaka City Med J; 2013 Jun; 59(1):45-52. PubMed ID: 23909080
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.
Saad F; Segal S; Eastham J
Eur Urol; 2014 Jan; 65(1):146-53. PubMed ID: 22633317
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
[TBL] [Abstract][Full Text] [Related]
14. Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):185-94. PubMed ID: 22168786
[TBL] [Abstract][Full Text] [Related]
15. Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey.
Santini D; Pantano F; Riccardi F; Di Costanzo GG; Addeo R; Guida FM; Ceruso MS; Barni S; Bertocchi P; Marinelli S; Marchetti P; Russo A; Scartozzi M; Faloppi L; Santoni M; Cascinu S; Maiello E; Silvestris F; Tucci M; Ibrahim T; Masi G; Gnoni A; Comandone A; Fazio N; Conti A; Imarisio I; Pisconti S; Giommoni E; Cinieri S; Catalano V; Palmieri VO; Infante G; Aieta M; Trogu A; Gadaleta CD; Brunetti AE; Lorusso V; Silvestris N
PLoS One; 2014; 9(8):e105268. PubMed ID: 25170882
[TBL] [Abstract][Full Text] [Related]
16. Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.
Tanaka R; Yonemori K; Hirakawa A; Kinoshita F; Takahashi N; Hashimoto J; Kodaira M; Yamamoto H; Yunokawa M; Shimizu C; Fujimoto M; Fujiwara Y; Tamura K
Oncologist; 2016 Apr; 21(4):508-13. PubMed ID: 26975863
[TBL] [Abstract][Full Text] [Related]
17. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
Facchini G; Caraglia M; Santini D; Nasti G; Ottaiano A; Striano S; Maiolino P; Ruberto M; Fiore F; Tonini G; Budillon A; Iaffaioli RV; Zeppetella GL
J Exp Clin Cancer Res; 2007 Sep; 26(3):307-12. PubMed ID: 17987788
[TBL] [Abstract][Full Text] [Related]
18. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).
Smith MR; Halabi S; Ryan CJ; Hussain A; Vogelzang N; Stadler W; Hauke RJ; Monk JP; Saylor P; Bhoopalam N; Saad F; Sanford B; Kelly WK; Morris M; Small EJ
J Clin Oncol; 2014 Apr; 32(11):1143-50. PubMed ID: 24590644
[TBL] [Abstract][Full Text] [Related]
19. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer.
Zaghloul MS; Boutrus R; El-Hossieny H; Kader YA; El-Attar I; Nazmy M
Int J Clin Oncol; 2010 Aug; 15(4):382-9. PubMed ID: 20354750
[TBL] [Abstract][Full Text] [Related]
20. Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
Murphy L; McCarthy J; McCrate F; Laing K; Powell E; Seal M; Edwards S
Support Care Cancer; 2013 Jun; 21(6):1557-60. PubMed ID: 23334521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]